Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer
Source:
Nasdaq GlobeNewswire
/
12 Oct 2022 07:00:01 America/Chicago
N/A
Share on,